@article{1c5e4ed8d24d4a03b741d470ca48220d,
title = "Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries",
abstract = "We examined the incidence of and risk factors for tuberculosis during the first year of highly active antiretroviral therapy in low-income (4540 patients) and high-income (22,217 patients) countries. Although incidence was much higher in low-income countries, the reduction in the incidence of tuberculosis associated with highly active antiretroviral therapy was similar: the rate ratio for months 7-12 versus months 1-3 was 0.48 (95% confidence interval, 0.36-0.64) in low-income countries and 0.36 (95% confidence interval, 0.26-0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings.",
author = "Brinkhof, {Martin W.G.} and Matthias Egger and Andrew Boulle and Margaret May and Mina Hosseinipour and Eduardo Sprinz and Paula Braitstein and Fran{\c c}ois Dabis and Peter Reiss and Bangsberg, {David R.} and Martin Rickenbach and Miro, {Jose M.} and Landon Myer and Amanda Mocroft and Denis Nash and Olivia Keiser and Margaret Pascoe and {Van Der Borght}, Stefaan and Mauro Schechter and Martin Brinkhof",
note = "Funding Information: Financial support. The ART-LINC Collaboration is funded by the US National Institutes of Health (Office of AIDS Research) and the French Agence Nationale de Recherches sur le Sida (ANRS). The ART Cohort Collaboration is funded by the UK Medical Research Council. Funding Information: Potential conflicts of interest. M.M. has received travel grants from GlaxoSmithKline. P.R. has received research funding from Boehringer-In-gelheim and Merck and has received honoraria for speaking engagements or advisory board participation from Gilead Sciences, Boehringer-Ingel-heim, Roche, Tibotec, GlaxoSmithKline, and Theratechnologies. J.M.M. has received recent research funding or honoraria as speaker/consultant from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Chiron, Cubist, Merck, Novartis, GlaxoSmithKline, Gilead Sciences, Oxford Immunotec, Pfizer, Roche, and Theravance. A.M. has received a consultancy honorarium from Bristol-Myers Squibb. All other authors: no conflicts.",
year = "2007",
month = dec,
day = "1",
doi = "10.1086/522986",
language = "English (US)",
volume = "45",
pages = "1518--1521",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "11",
}